A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Study ID
- NCT05367687
- Phase
- PHASE2
- Status
- Completed
Conditions
- Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Camrelizumab、Rivoceranib — DRUGCamrelizumab: 200 mg, intravenous infusion. Rivoceranib: 250 mg, oral.
- Camrelizumab — DRUGCamrelizumab: 200 mg, intravenous infusion.
Study Details
A Trial to Evaluate the Efficacy and Safety of Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation.
Key Dates
- Start date
- Sep 1, 2022
- Status verified
- Nov 2025
- Primary completion
- Nov 15, 2024
- Completion
- Nov 15, 2024
Study Design
- Enrollment
- 251 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment groupCamrelizumab Plus Rivoceranib (Apatinib)
- Active Comparator: Control groupCamrelizumab
Primary Outcome Measure
Recurrence-Free Survival (RFS), as Determined by the investigator [ Time Frame: Randomization up to approximately 43 months ]